ZA200502177B - Inhalation composition - Google Patents

Inhalation composition Download PDF

Info

Publication number: ZA200502177B
Authority: ZA; South Africa
Prior art keywords: dry powder; microns; lactose; medicament; inhalation composition
Prior art date: 2002-08-21

Application number

ZA200502177A

Other languages

English (en)

Inventor

Xian-Ming Zeng

Original Assignee

Norton Healthcare Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-21

Filing date

2005-03-15

Publication date

2006-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9942746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200502177(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-03-15 Application filed by Norton Healthcare Ltd filed Critical Norton Healthcare Ltd

2006-05-31 Publication of ZA200502177B publication Critical patent/ZA200502177B/en

Links

239000000203 mixture Substances 0.000 title claims description 102
239000003814 drug Substances 0.000 claims description 60
239000002245 particle Substances 0.000 claims description 53
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 51
239000008101 lactose Substances 0.000 claims description 51
239000000843 powder Substances 0.000 claims description 37
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 26
238000000034 method Methods 0.000 claims description 26
229960002848 formoterol Drugs 0.000 claims description 25
229940112141 dry powder inhaler Drugs 0.000 claims description 11
RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 claims description 5
229960003610 formoterol fumarate dihydrate Drugs 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 2
229960001375 lactose Drugs 0.000 description 42
229940079593 drug Drugs 0.000 description 17
239000010419 fine particle Substances 0.000 description 13
238000009826 distribution Methods 0.000 description 11
239000000546 pharmaceutical excipient Substances 0.000 description 9
239000002775 capsule Substances 0.000 description 8
238000009472 formulation Methods 0.000 description 7
239000013065 commercial product Substances 0.000 description 6
238000002156 mixing Methods 0.000 description 6
230000008569 process Effects 0.000 description 6
239000004480 active ingredient Substances 0.000 description 5
-1 and the like) Substances 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
150000001875 compounds Chemical class 0.000 description 4
230000008021 deposition Effects 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
238000011282 treatment Methods 0.000 description 4
229960003556 aminophylline Drugs 0.000 description 3
FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000005070 sampling Methods 0.000 description 3
238000007873 sieving Methods 0.000 description 3
238000003860 storage Methods 0.000 description 3
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 2
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
229930182837 (R)-adrenaline Natural products 0.000 description 2
NWLPAIVRIWBEIT-SEPHDYHBSA-N (e)-but-2-enedioic acid;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O NWLPAIVRIWBEIT-SEPHDYHBSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
239000000048 adrenergic agonist Substances 0.000 description 2
229940126157 adrenergic receptor agonist Drugs 0.000 description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
229940092705 beclomethasone Drugs 0.000 description 2
229940124630 bronchodilator Drugs 0.000 description 2
239000000168 bronchodilator agent Substances 0.000 description 2
229960004436 budesonide Drugs 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000000812 cholinergic antagonist Substances 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
229960002819 diprophylline Drugs 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 description 2
229960005139 epinephrine Drugs 0.000 description 2
229960000676 flunisolide Drugs 0.000 description 2
229960001361 ipratropium bromide Drugs 0.000 description 2
KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
229960002657 orciprenaline Drugs 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 2
229960002052 salbutamol Drugs 0.000 description 2
229960004017 salmeterol Drugs 0.000 description 2
239000000126 substance Substances 0.000 description 2
229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 2
229960000195 terbutaline Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
230000009969 flowable effect Effects 0.000 description 1
229960000193 formoterol fumarate Drugs 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000002664 inhalation therapy Methods 0.000 description 1
230000003434 inspiratory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000002356 laser light scattering Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000011112 process operation Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
238000005563 spheronization Methods 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Otolaryngology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA200502177A 2002-08-21 2005-03-15 Inhalation composition ZA200502177B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB0219513A GB0219513D0 (en)	2002-08-21	2002-08-21	Inhalation compositions including coarse carrier

Publications (1)

Publication Number	Publication Date
ZA200502177B true ZA200502177B (en)	2006-05-31

Family

ID=9942746

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200502177A ZA200502177B (en)	2002-08-21	2005-03-15	Inhalation composition

Country Status (8)

Country	Link
BR (1)	BRPI0313647A2 (fr)
CA (1)	CA2499273C (fr)
ES (1)	ES2371601T3 (fr)
GB (1)	GB0219513D0 (fr)
NO (1)	NO20051461L (fr)
TN (1)	TNSN05047A1 (fr)
WO (1)	WO2004017914A2 (fr)
ZA (1)	ZA200502177B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2007533387A (ja)	2004-04-21	2007-11-22	イノベータバイオメドリミテッド	吸入器
PL2708225T3 (pl)	2004-04-23	2019-07-31	Cydex Pharmaceuticals, Inc.	Formulacja DPI zawierająca eter sulfoalkilowy cyklodekstryny
GB0409197D0 (en)	2004-04-24	2004-05-26	Innovata Biomed Ltd	Device
WO2006086270A1 (fr)	2005-02-10	2006-08-17	Glaxo Group Limited	Procedes de fabrication du lactose au moyen de techniques de pre-classification et preparations pharmaceutiques ainsi obtenues
US7629331B2 (en)	2005-10-26	2009-12-08	Cydex Pharmaceuticals, Inc.	Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
GB0605723D0 (en)	2006-03-23	2006-05-03	3M Innovative Properties Co	Powder filling processes
WO2008134817A1 (fr) *	2007-05-03	2008-11-13	The University Of Sydney	Vecteurs composites pour thérapie par inhalation de poudre sèche
TR201205852A2 (tr) *	2011-06-02	2012-12-21	Bi̇lgi̇ç Mahmut	Geliştirilmiş yeni kuru toz formülasyonu.
TR201105367A2 (tr) *	2011-06-02	2012-12-21	Bi̇lgi̇ç Mahmut	Akış özellikleri geliştirilmiş bir kuru toz formülasyonu.
UA115989C2 (uk)	2012-07-05	2018-01-25	Арвен Айлак Санайі Ве Тіджарет А.С.	Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
EP2874928B1 (fr)	2012-07-19	2016-06-15	Adamis Pharmaceuticals Corporation	Appareil d'acheminement de poudre
JP6251667B2 (ja)	2014-06-03	2017-12-20	アサヒカルピスウェルネス株式会社	錠剤型即放性製剤及びその製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU756852B2 (en) *	1998-11-13	2003-01-23	Jagotec Ag	Dry powder for inhalation
DE69818872T2 (de) *	1998-12-11	2004-05-19	Pharmachemie B.V.	Pharmazeutische zubereitungen zur inhalation eines opioids
ATE275391T1 (de)	2000-10-12	2004-09-15	Boehringer Ingelheim Pharma	Neue tiotropium-haltige inhalationspulver
UA75375C2 (en)	2000-10-12	2006-04-17	Boehringer Ingelheim Pharma	Method for producing powdery preparations for inhaling

2002
- 2002-08-21 GB GB0219513A patent/GB0219513D0/en not_active Ceased
2003
- 2003-08-21 WO PCT/US2003/026385 patent/WO2004017914A2/fr not_active Ceased
- 2003-08-21 BR BRPI0313647A patent/BRPI0313647A2/pt active Search and Examination
- 2003-08-21 ES ES03751884T patent/ES2371601T3/es not_active Expired - Lifetime
- 2003-08-21 CA CA2499273A patent/CA2499273C/fr not_active Expired - Fee Related
2005
- 2005-02-18 TN TNP2005000047A patent/TNSN05047A1/en unknown
- 2005-03-15 ZA ZA200502177A patent/ZA200502177B/en unknown
- 2005-03-18 NO NO20051461A patent/NO20051461L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2499273C (fr)	2011-06-21
BRPI0313647A2 (pt)	2019-02-19
WO2004017914A3 (fr)	2004-04-29
TNSN05047A1 (en)	2007-05-14
WO2004017914A2 (fr)	2004-03-04
CA2499273A1 (fr)	2004-03-04
NO20051461L (no)	2005-05-20
GB0219513D0 (en)	2002-10-02
ES2371601T3 (es)	2012-01-05
WO2004017914A8 (fr)	2005-07-07

Publication	Publication Date	Title
US20060292083A1 (en)	2006-12-28	Inhalation compositions with high drug ratios
US8075873B2 (en)	2011-12-13	Method of preparing dry powder inhalation compositions
CA2499273C (fr)	2011-06-21	Compositions a inhaler
US8273331B2 (en)	2012-09-25	Inhalation compositions
CN107496388B (zh)	2020-12-15	一种含有福莫特罗和噻托铵盐组合物的粉状制剂及其制备方法
US20050158248A1 (en)	2005-07-21	Method of preparing dry powder inhalation compositions
EP1699434A1 (fr)	2006-09-13	Procede de preparation d'un medicament
JP2013177429A (ja)	2013-09-09	吸入組成物
CN1694712A (zh)	2005-11-09	吸入组合物
HK1160601A (en)	2012-08-10	Inhalation composition
CN114344285A (zh)	2022-04-15	改良的可吸入团聚物